ABBISKO-B(02256): Abbisko Therapeutics Announces Positive Preliminary Results from Phase II Clinical Study of Lavengratinib (ABSK061) for the Treatment of Achondroplasia

ABBISKO-B(02256) announced that its subsidiary, Shanghai Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics), announced positive preliminary efficacy results from the Phase II clinical study of its selective oral small molecule FGFR2/3 inhibitor lavengratinib (ABSK061) for the treatment of pediatric achondroplasia (ACH). In the initial and lowest dose cohort (0.064 mg/kg, once daily), after 27 weeks of lavengratinib treatment in ACH children aged 6 years and older, the annualized height velocity (AHV) increased by a mean of +2.4 cm/year from baseline, with a response rate of 100%. Lavengratinib was generally well tolerated, with no adverse events (AEs) related to FGFR1 or FGFR2 observed.